Chinese Tech Landscape Continues to Rise as Most-preferred VC Investment Destination
Chinese startups raised $104.4 Billion in VC funding in 2021, reveals GlobalData
Chinese Tech Landscape is growing tremendously despite China’s recent regulatory crackdown on technology giants. The restrictions have made little or no significant impact on the investments in Chinese startups. Global data reveals that 2021 investments in startups ushered the venture capital (VC) frenzy in the country. The VC market of the country in the wake of evolving regulatory landscape and COVID-19 pandemic surprisingly looks upbeat. Chinese startups raised $104.4 billion, a growth of 48.9% year-on-year in 2021, finds GlobalData, a leading data and analytics company.
Investments in Chinese Tech Landscape Grows at More than 30% YOY
An analysis of GlobalData’s Financial Deals Database reveals that deal volume too witnessed a staggering 31.9% growth from 3,261 in 2020 to 4,302 in 2021.
Aurojyoti Bose, Lead Analyst at GlobalData, comments: “Investors seemed to have become wary of China for some time on the back of a series of regulatory crackdowns on domestic companies. However, funding activity picked soon after a brief downturn. The announcement of several big-ticket deals during 2021 reflects investors’ appetite for placing bets on China is still bullish.”
Despite the year-on-year growth, the month-on-month funding trend remained inconsistent throughout 2021. Interestingly, there was a decline in deal volume in December while deal value grew significantly, and, in fact, it was the best month in terms of value during the year.
In fact, December 2021 alone witnessed the announcement of 32 $100 million+ deals while 76 such deals were announced during the last quarter and a total of 262 deals in this range were announced during the year.
Biggest Startup Investments in Chinese Tech Landscape
Some of the notable VC funding deals announced in China during 2021 include $1.6 billion raised by SVOLT Energy in August, $1.5 billion capital raised by Horizon Robotics in June, $1.2bn raised by Nanjing Lingxing Technology (T3 Travel) in October, $700 million funding raised by Abogen Biosciences in August, and $750 million capital raised by Beijing Shihui Technology in March.
Jemima Walker, Analyst in the Thematic Research team at GlobalData, recently said “The development of technologies such as 5G, augmented reality (AR), cybersecurity, autonomous vehicles, and cloud computing will allow healthcare providers to fully embrace the transition into digitalized services. There are opportunities for digital and virtual tools to help in many healthcare services, including mental health treatments, chronic pain management, stroke rehabilitation, opioid addiction therapy, and even in the development of autonomous, connected ambulances.”
Jemima continued, “Medical robotics is a fast-growing field, with the surgical robotics segment leading the market. While COVID-19 caused the cancellation of an estimated 15% to 30% of elective surgeries from April 2020, there will still be 3.7 million robotic surgical procedures in 2022.”
“However, the high costs of medical robots, and the additional training often required, will prevent quick, widespread adoption. Instead, for-profit entities will act as early leaders — particularly in the outpatient ‘same day’ surgery center sector. Early adopters will then lead to an explosion of adoption within hospitals and more public-based healthcare systems such as the NHS.”
In 2022, we can expect more VC fundings to happen in the Chinese tech landscape despite regulations by the country’s regime. We can speculate that emerging capabilities in 5G, AI, Nano technology, healthcare Cloud, computing, and Blockchain engineering would remain the biggest avenues for VC funding in the Chinese calendar for 2022.
[To share your insights with us, please write to email@example.com]